NYXH - הכנסה תפעולית לפני ניכוי פחת Nyxoah

Absolute EBITDA on the GURU.Markets chart confirms the effectiveness of Nyxoah S.A. (NYXH) diversifying its plants across the US and Europe to secure implant supplies. The value 0.00 reflects the latest metric as the company navigates high launch costs for sales in both regions. The Belgian innovator is gaining physician trust by offering unique nerve stimulation as an alternative to CPAP masks for apnea.
פילוחי נתונים אנליטיים מרוכזים עבור Nyxoah, S.A. (NYXH)

A comparative asset analysis requires an evaluation of real cash flow, where this metric measures operating efficiency stripped of depreciation and taxes to determine the actual margin of safety. For Nyxoah S.A. (NYXH), this calculation reflects the ability to fund the expansion of the Genio system and regulatory costs in the US, making the cash EBITDA figure a key indicator of the viability of its market capture strategy.